Immunovant Inc’s recent filing unveils that its Director Fromkin Andrew J. unloaded Company’s shares for reported $0.16 million on Mar 07 ’25. In the deal valued at $19.60 per share,8,000 shares were sold. As a result of this transaction, Fromkin Andrew J. now holds 91,913 shares worth roughly $1.69 million.
Then, ANDREW J FROMKIN bought 8,000 shares, generating $156,160 in total proceeds.
Before that, Macias William L. sold 2,055 shares. Immunovant Inc shares valued at $42,867 were divested by the Chief Medical Officer at a price of $20.86 per share. As a result of the transaction, Macias William L. now holds 357,353 shares, worth roughly $6.56 million.
Jefferies initiated its Immunovant Inc [IMVT] rating to a Hold in a research note published on March 03, 2025; the price target was $20. A number of analysts have revised their coverage, including Wolfe Research’s analysts, who decreased its forecast for the stock in early January from “an Outperform” to “a Peer perform”. Oppenheimer maintained its rating on October 09, 2024. It rated IMVT as “an Outperform”.
Price Performance Review of IMVT
On Friday, Immunovant Inc [NASDAQ:IMVT] saw its stock fall -2.24% to $18.37. Over the last five days, the stock has lost -6.47%. Immunovant Inc shares have fallen nearly -25.84% since the year began. Nevertheless, the stocks have fallen -41.55% over the past one year. While a 52-week high of $34.47 was reached on 01/02/25, a 52-week low of $17.01 was recorded on 03/19/25. SMA at 50 days reached $20.43, while 200 days put it at $26.42.
Levels Of Support And Resistance For IMVT Stock
The 24-hour chart illustrates a support level at 18.04, which if violated will result in even more drops to 17.71. On the upside, there is a resistance level at 18.76. A further resistance level may holdings at 19.15. The Relative Strength Index (RSI) on the 14-day chart is 42.05, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.70, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 60.35%. Stochastics %K at 37.25% indicates the stock is a holding.
How much short interest is there in Immunovant Inc?
A steep rise in short interest was recorded in Immunovant Inc stocks on 2025-03-14, growing by 1.01 million shares to a total of 15.8 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-14 was 14.79 million shares. There was a rise of 6.4%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on March 28, 2024 when Oppenheimer began covering the stock and recommended ‘”an Outperform”‘ rating along with a $50 price target.
